ÂÜÀòÂÒÂ×

Georg Duenstl is currently the VP of Drug Discovery at DeepCure. Prior to this, they were an Associate Research Fellow at LEO Pharma from July 2020 to January 2022. In this role, they were responsible for identifying new technologies and next-generation therapies. Georg also provided scientific and strategic guidance to R&D leadership up to EVP level. From August 2008 to January 2016, they were the Principal Scientist for Front-End Innovation / NME Ideation. In this role, they were responsible for driving the ideation process and for converting ideas into R&D projects with a clear differentiation potential. Georg also managed existing collaborations and evaluated licensing opportunities and potential collaboration partners.

Georg Duenstl has a certificate from the MIT Sloan School of Management in Advanced Certificate for Executives in Management, Innovation, and Technology. Georg also has a certificate from the Wharton School of Business in Wharton Certificate of Professional Development. Georg has a Master of Science in Biochemistry and Molecular Biology from the University of Konstanz, and they have a Doctor of Philosophy in Biochemical Pharmacology from the University of Konstanz.

They work with Jacob Gillis - Senior Scientific Program Manager, Michal Segal Salto - Associate Research Fellow, Biology, and Eddy Pichinuk - Principal Scientist & Head, Screening Technologies & Bioassays. Georg Duenstl reports to Joseph Jacobson, Co-Founder & CSO.